Related Experiment Video

Updated: Sep 6, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

Yeast Microcapsule Mediated Natural Products Delivery for Treating Ulcerative Colitis through Anti-Inflammatory and

Xingxing Feng1, Qi Xie1, Hongbo Xu1

  • 1Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.

ACS Applied Materials & Interfaces
|June 30, 2022
PubMed

Insights

A novel oral drug delivery system, BBR/MPN@YM, effectively targets M2 macrophages for ulcerative colitis (UC) treatment. This system utilizes natural anti-inflammatory compounds, berberine (BBR) and Epigallocatechin Gallate (EGCG), to reduce inflammation and improve UC therapy.

Area of Science:

  • Gastroenterology
  • Immunology
  • Drug Delivery Systems

Background:

  • Ulcerative colitis (UC) is a prevalent inflammatory bowel disease causing significant patient distress.
  • M2 macrophages are recognized for their anti-inflammatory properties, presenting a therapeutic target for UC.
  • Current UC treatments may have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To design and evaluate a safe, oral drug delivery system targeting macrophages for UC treatment.
  • To investigate the synergistic anti-inflammatory effects of berberine (BBR) and Epigallocatechin Gallate (EGCG) encapsulated in a yeast microcapsule (YM).
  • To assess the efficacy of the BBR/MPN@YM system in modulating macrophage polarization in a UC mouse model.

Main Methods:

  • Development of a yeast microcapsule (YM) encapsulating berberine (BBR) and Epigallocatechin Gallate (EGCG) to create the BBR/MPN@YM therapeutic system.
  • Utilizing the interaction between yeast β-1,3-d-glucan and macrophage dectin-1 receptors for targeted delivery.
  • Evaluating the system's anti-inflammatory effects and macrophage polarization in an in vivo UC mouse model.

Main Results:

  • BBR and EGCG demonstrated synergistic anti-inflammatory and antioxidant effects against UC.
  • The BBR/MPN@YM system was effectively delivered to inflamed tissues and internalized by macrophages, bypassing gastric degradation.
  • In vivo studies showed BBR/MPN@YM successfully converted M1 macrophages to anti-inflammatory M2 macrophages, reducing UC-related inflammation.

Conclusions:

  • The BBR/MPN@YM targeted oral drug delivery system offers a promising new strategy for UC therapy.
  • This system leverages natural compounds and targeted delivery to modulate macrophage function for specific anti-inflammatory effects.
  • The study highlights the potential of macrophage-targeting drug delivery for managing inflammatory bowel diseases like UC.
Keywords:
anti-inflammationmacrophage polarizationnatural productsulcerative colitisyeast microcapsule

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

912
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
232
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
199
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
263
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
592
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
142